You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
ARK持倉追蹤 | 加倉大量生物醫學公司

【Ark旗下基金持倉變化小結,2021年10月13日】

①ARK系列主動型ETF當日共操作16筆,其中買入13只股票,賣出3只股票。

②ARKG加倉CRISPR THERAPEUTICS,公司專注開發基於CRISPR/Cas9技術的基因編輯治療藥物,其技術可以對基因組DNA進行精確、定向的改變,可以用於β地中海貧血、血友病、杜氏肌營養不良症、囊性纖維化等疾病的治療。

③ARKG買入INTELLIA THERAPEUTICS, 公司CRISPR/Cas9技術能夠通過一個簡單的治療過程來編輯人體中的患病基因。 公司產品組合包括CRISPR/Cas9平臺技術、注射技術以及用於人類治療用途的核酸修改技術。

④ARKK加倉BEAM THERAPEUTICS,致力於根據公司專有的鹼基對編輯技術來創建一類新型的精密基因藥物,其願景是爲患有嚴重疾病的患者提供終生治療

【ARK系列ETF介紹】

①ARKK:以顛覆性創新產業爲主要投資標的

ARKK專門投資革命性創新的公司,在5個美股ETF中,ARKK投資的公司類型最多元化,包括基因科技、全自動化、物聯網及金融科技相關的公司,可以說是其餘4個ETF的合體。

②ARKQ:以自動科技自動機器人技術爲主要投資標的

ARKQ投資的公司專注於機器人自動化相關的公司,當中投資自動駕駛的公司佔比最多,其次爲自動化機器人、3D打印、儲能技術、太空探索等的相關公司。

③ARKF :以金融科技創新爲主要投資標的

ARKF主力投資金融科技相關公司,其中包括交易平臺、區塊鏈、衆籌平臺等等相關公司。

④ ARKW:以"下一代網絡"爲主要投資標的

ARKW專門投資"下一代網絡"的公司,當中佔比最多的公司爲雲計算、其次爲網絡安全、電子商務、大數據、人工智能等相關公司。

⑤ ARKG:以生物基因科技創新爲主要投資標的

ARKG這隻ETF主要專注於基因革命領域,包括基因編輯技術CRISPR、基因診斷治療、靶向治療、生物信息。

【uSMART目前支持部分美股10倍槓桿日內交易】

以上數據爲Cathie Wood個人/所在機構的過往操作,其交易背後之投資邏輯並不明確,不代表投資建議,注意風險

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account